Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Corrigendum to "The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors" [Pharmacol. Res. 147 (2019) 104392].

Bechman K, Yates M, Galloway JB.

Pharmacol Res. 2020 Mar;153:104634. doi: 10.1016/j.phrs.2020.104634. Epub 2020 Feb 1. No abstract available.

PMID:
32014340
2.

Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register.

Bechman K, Oke A, Yates M, Norton S, Dennison E, Cope AP, Galloway JB.

Rheumatology (Oxford). 2020 Jan 30. pii: kez671. doi: 10.1093/rheumatology/kez671. [Epub ahead of print]

PMID:
31998962
3.

Defining and measuring imaging appropriateness in low back pain studies: a scoping review.

Yates M, Oliveira CB, Galloway JB, Maher CG.

Eur Spine J. 2020 Mar;29(3):519-529. doi: 10.1007/s00586-019-06269-7. Epub 2020 Jan 14. Review.

PMID:
31938944
4.

Variation and implications of treatment decisions in early rheumatoid arthritis: results from a nationwide cohort study.

Yates M, MacGregor AJ, Ledingham J, Norton S, Bechman K, Dennison EM, Galloway JB.

Rheumatology (Oxford). 2019 Dec 5. pii: kez550. doi: 10.1093/rheumatology/kez550. [Epub ahead of print]

PMID:
31803913
5.

Determining responsiveness and meaningful changes for the Musculoskeletal Health Questionnaire (MSK-HQ) for use across musculoskeletal care pathways.

Price AJ, Ogollah R, Kang S, Hay E, Barker KL, Benedetto E, Smith S, Smith J, Galloway JB, Ellis B, Rees J, Glyn-Jones S, Beard D, Fitzpatrick R, Hill JC.

BMJ Open. 2019 Oct 3;9(10):e025357. doi: 10.1136/bmjopen-2018-025357.

6.

Rising Incidence of Acute Hospital Admissions due to Gout.

Russell MD, Yates M, Bechman K, Rutherford AI, Subesinghe S, Lanyon P, Galloway JB.

J Rheumatol. 2020 Apr;47(4):619-623. doi: 10.3899/jrheum.190257. Epub 2019 Sep 15.

PMID:
31523046
7.

The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors.

Bechman K, Yates M, Galloway JB.

Pharmacol Res. 2019 Sep;147:104392. doi: 10.1016/j.phrs.2019.104392. Epub 2019 Aug 8. Review. Erratum in: Pharmacol Res. 2020 Mar;153:104634.

8.

Placebo Response in Rheumatoid Arthritis Clinical Trials.

Bechman K, Yates M, Norton S, Cope AP, Galloway JB.

J Rheumatol. 2020 Jan;47(1):28-34. doi: 10.3899/jrheum.190008. Epub 2019 May 1.

PMID:
31043548
9.

Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Bechman K, Clarke BD, Rutherford AI, Yates M, Nikiphorou E, Molokhia M, Norton S, Cope AP, Hyrich KL, Galloway JB.

Rheumatology (Oxford). 2019 Oct 1;58(10):1767-1776. doi: 10.1093/rheumatology/kez037.

PMID:
30982886
10.

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.

Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, Winthrop KL, Galloway JB.

Rheumatology (Oxford). 2019 Oct 1;58(10):1755-1766. doi: 10.1093/rheumatology/kez087.

PMID:
30982883
11.

Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes.

Bechman K, Tweehuysen L, Garrood T, Scott DL, Cope AP, Galloway JB, Ma MHY.

J Rheumatol. 2018 Nov;45(11):1515-1521. doi: 10.3899/jrheum.171375. Epub 2018 Sep 1.

12.

Biologic prescribing decisions following serious infection: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.

Subesinghe S, Rutherford AI, Byng-Maddick R, Hyrich KL, Galloway JB.

Rheumatology (Oxford). 2018 Dec 1;57(12):2096-2100. doi: 10.1093/rheumatology/key198.

PMID:
29986108
13.

Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB.

Ann Rheum Dis. 2018 Jun;77(6):905-910. doi: 10.1136/annrheumdis-2017-212825. Epub 2018 Mar 28.

PMID:
29592917
14.

A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis.

Subesinghe S, Bechman K, Rutherford AI, Goldblatt D, Galloway JB.

J Rheumatol. 2018 Jun;45(6):733-744. doi: 10.3899/jrheum.170710. Epub 2018 Mar 15.

PMID:
29545454
15.

Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB.

Rheumatology (Oxford). 2018 Jun 1;57(6):997-1001. doi: 10.1093/rheumatology/key023.

PMID:
29529307
16.

Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?

Ibrahim F, Lorente-Cánovas B, Doré CJ, Bosworth A, Ma MH, Galloway JB, Cope AP, Pande I, Walker D, Scott DL.

Rheumatology (Oxford). 2017 Nov 1;56(11):2004-2014. doi: 10.1093/rheumatology/kex315.

17.

Hydroxychloroquine use: the potential impact of new ocular screening guidelines.

Yates M, Malaiya R, Stack J, Galloway JB.

Eye (Lond). 2018 Jan;32(1):161-162. doi: 10.1038/eye.2017.166. Epub 2017 Aug 11. No abstract available.

18.

Response to: 'Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?' by Nocturne et al.

Mercer LK, Galloway JB, Lunt M, Davies R, Low AA, Dixon WG, Watson KD, Symmons DP, Hyrich KL.

Ann Rheum Dis. 2017 Feb;76(2):e4. doi: 10.1136/annrheumdis-2016-210631. Epub 2016 Dec 1. No abstract available.

PMID:
27934677
19.

A population study of the reported incidence of native joint septic arthritis in the United Kingdom between 1998 and 2013.

Rutherford AI, Subesinghe S, Bharucha T, Ibrahim F, Kleymann A, Galloway JB.

Rheumatology (Oxford). 2016 Dec;55(12):2176-2180. Epub 2016 Sep 16.

PMID:
27638811
20.

Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Mercer LK, Galloway JB, Lunt M, Davies R, Low AL, Dixon WG, Watson KD; BSRBR Control Centre Consortium, Symmons DP, Hyrich KL.

Ann Rheum Dis. 2017 Mar;76(3):497-503. doi: 10.1136/annrheumdis-2016-209389. Epub 2016 Aug 8.

21.

Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data.

Pratt AG, Lendrem D, Hargreaves B, Aslam O, Galloway JB, Isaacs JD.

Rheumatology (Oxford). 2016 Oct;55(10):1843-8. doi: 10.1093/rheumatology/kew261. Epub 2016 Jul 3.

22.

Biosimilars in rheumatology: out of the laboratory and into practice.

Rutherford AI, Galloway JB.

Expert Rev Clin Immunol. 2016 Jul;12(7):697-9. doi: 10.1080/1744666X.2016.1191946. Epub 2016 Jun 1. No abstract available.

PMID:
27195989
23.

Delivering future clinical trials in rheumatology.

Galloway JB, Scott DL.

J Rheumatol. 2015 Jan;42(1):18-20. doi: 10.3899/jrheum.141270. No abstract available.

PMID:
25554806
24.

The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA.

Závada J, Lunt M, Davies R, Low AS, Mercer LK, Galloway JB, Watson KD, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium.

Ann Rheum Dis. 2014 Jan;73(1):252-5. doi: 10.1136/annrheumdis-2012-203102. Epub 2013 May 5.

PMID:
23644671
25.

Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.

Mercer LK, Davies R, Galloway JB, Low A, Lunt M, Dixon WG, Watson KD, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium.

Rheumatology (Oxford). 2013 Jan;52(1):91-8. doi: 10.1093/rheumatology/kes350.

26.

Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix.

Mercer LK, Low AS, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL; BSRBR Control Centre Consortium.

Ann Rheum Dis. 2013 Jan;72(1):143-4. doi: 10.1136/annrheumdis-2012-201814. Epub 2012 Jul 26. No abstract available.

PMID:
22843488
27.

Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.

Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, Watson KD, Lunt M, Hyrich KL, Symmons DP.

Ann Rheum Dis. 2013 Feb;72(2):229-34. doi: 10.1136/annrheumdis-2011-201108. Epub 2012 Apr 24.

28.

The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.

Mercer LK, Green AC, Galloway JB, Davies R, Lunt M, Dixon WG, Watson KD; British Society for Rheumatology Biologics Register Control Centre Consortium, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register.

Ann Rheum Dis. 2012 Jun;71(6):869-74. doi: 10.1136/annrheumdis-2011-200622. Epub 2012 Jan 12.

29.

Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.

Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, Watson KD, Lunt M, Symmons DP; BSR Biologics Register.

Ann Rheum Dis. 2011 Oct;70(10):1810-4. doi: 10.1136/ard.2011.152769. Epub 2011 Jul 21.

30.

Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.

Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL; BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register.

Ann Rheum Dis. 2011 Oct;70(10):1831-4. doi: 10.1136/ard.2011.153536. Epub 2011 Jul 22.

31.

The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Watson KD, Lunt M; BSRBR Control Centre Consortium, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2011 Jul;50(7):1341-2. doi: 10.1093/rheumatology/ker146. Epub 2011 Apr 12. No abstract available.

PMID:
21489973
32.

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.

Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, Symmons DP; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2011 Jan;50(1):124-31. doi: 10.1093/rheumatology/keq242. Epub 2010 Jul 31.

33.

Vagotomy and pyloric dilatation in chronic duodenal ulceration.

Thomson JD, Galloway JB.

Br Med J. 1979 Jun 2;1(6176):1453-5.

34.

Perforation of the intestine due to muscular violence.

Galloway JB, McKirdy H.

Br Med J. 1966 Dec 31;2(5530):1636. No abstract available.

Supplemental Content

Loading ...
Support Center